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Enzyme replacement therapy (ERT) with recombinant human
a-galactosidase A (r-haGalA) enhances microvascular
globotriaosylceramide clearance and improves clinical
symptoms in patients with Fabry disease. We evaluated
whether these effects are translated into a long-term benefit
of kidney and heart function. We did a single center,
prospective, open label study in 26 patients with Fabry
disease (one early death, follow-up in 25 patients). r-a-GalA
was administered in a dosage of 1 mg/kg body weight every
second week. The effect of therapy on clinical end points
(death, cardiac and cerebrovascular event, renal failure),
cardiac and renal function monitored by Doppler
echocardiography, 99Tc-GFR, and proteinuria was
investigated. After a mean treatment time of 2378 months,
nine patients experienced 12 end points, including two
deaths. All end points occurred in patients with impaired
renal function (n¼ 16; GFR 71717 ml/min/1.73 m2). Despite
ERT, renal function deteriorated to 60723 ml/min/1.73 m2
(P¼ 0.04) and left ventricular posterior wall thickness (PWT)
did not change (14.072.1 vs 13.472.3 mm). In contrast,
patients without impairment of renal function (n¼ 9) had a
more favorable outcome (no clinical events; GFR 115718 vs
102714 ml/min/1.73 m2, NS; PWT 11.771 and 10.770.7 mm,
P¼ 0.04). Proteinuria remained unchanged (1.3470.94 vs
1.0170.97 g/day, n¼ 10). Patients with impaired renal
function have a less favorable outcome and may develop
cardiovascular and renal end points despite ERT.
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Fabry disease is a life-threatening X-linked lysosomal storage
disorder due to a variety of mutations in the gene encoding
for the lysosomal enzyme a-Galactosidase A (a-GalA). The
resulting deficiency of a-GalA causes progressive intracellular
accumulation of glycosphingolipids, mainly globotriaosylcer-
amides (GL3). In childhood, the disease presents with
acroparaesthesia, angiokeratoma, and anhidrosis. Further
accumulation of GL3 in cells of the kidney, heart, and
nervous system culminates in progressive organ failure.1 In
affected males, severe morbidity is caused by heart failure,
arrhythmias, stroke, or end-stage renal disease.1,2 Enzyme
replacement therapy (ERT) with recombinant human a-GalA
(r-haGalA) reduces lysosomal GL3 deposition. Phase I and II
clinical trials demonstrated safety and efficacy.3,4 A rando-
mised, double-blind and placebo-controlled multicenter
study with 1 mg/kg r-haGalA in 58 patients showed a nearly
complete clearance of GL3 in vascular endothelium of
kidneys, heart, and skin.5,6
Subsequently patients were enrolled in an open label
extension trial and continued safety and efficacy in respect to
stabilization of serum creatinine and sustained GL3 clearance
in capillary endothelium of skin specimens was demon-
strated.7 Another controlled study demonstrated a decline of
neuropathic pain.8 However, the clinical benefit of ERT in
Fabry patients with multiple organ involvement, such as
cardiomyopathy and chronic kidney disease over prolonged
periods of time, is unknown. Aim of this study was to
evaluate the impact of ERT on heart and kidney function in a
group of 26 patients with different stages of Fabry disease.
RESULTS
Patient demographic data
In total, 26 patients with Fabry disease were found eligible for
ERT because of severe symptoms and organ manifestation
after diagnosis had been confirmed by measurement of
a-GalA activity in serum and by mutational analysis. Results
of enzyme activity and mutational analysis have previously
been described in a subgroup of 16 patients.9 Two sisters
(patients no. 10 and 24, see Table 1b) with proteinuria and
clinical symptoms underwent renal biopsy and widespread
GL3 deposition within the glomeruli justified inclusion into
this study. One patient died after 10 months of ERT prior to
follow-up evaluation. Baseline data of this patient are not
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included in this study. A history of acroparesthesia was
reported in 23 patients, hypohidrosis was documented in 18
patients and angiokeratoma were found in 23 patients. At
presentation, eight patients had chronic kidney disease stages
4 or 5, five patients were on renal replacement therapy; two
on hemodialysis treatment since 5 and 7 years respectively,
and three patients had received a kidney graft 2, 3, and 12
years ago. Mean age of the nine patients with a GFR490 ml/
min2 was 3977.7 years. Those with GFRo90 ml/min2 were
4379.5 years old (n¼ 16). There was no significant
correlation between age and GFR. Concomitant drug therapy
at baseline consisted of diuretics (n¼ 7), aspirin (n¼ 7), ACE
inhibitors and Angiotensin-I blocker (n¼ 6), b blocker
(n¼ 4), non-dihydropyridine calcium channel blocker
(n¼ 2), and statins (n¼ 1) and was continued throughout
the study (see Tables 1a and b). Among the 12 patients who
were classified as hypertensive, five were well controlled and
achieved target blood pressure below 130/80 mmHg, seven
had values above 130/80 mmHg (mean blood pressure
110724/74711 and 147710/9179 mmHg respectively).
Blood pressure was normal in the remaining patients
(119717/80711 mmHg). Serum concentration of total
cholesterol and low-density lipoprotein cholesterol at base-
line was 194738 and 114730 mg/dl, respectively. There was
no significant change at follow-up (185733 and
103744 mg/dl). Statins were taken by one patient. Anti-
hypertensive and antiproteinuric medication and baseline
characteristics of the patients as well as major manifestation
of the disease are presented in Tables 1a and b.
Follow-up and ERT
Twenty-five patients were evaluated after a mean observation
time of 2378 months (range 12–37 months) during ERT. In
general, ERT was well tolerated. No serious side effects
occurred. Most patients reported fatigue like symptoms up to
12 h after infusion. Chills and shivering during enzyme
administration were observed occasionally in six patients,
one was temporarily treated with oral steroids.
Clinical findings. No patient had to stop or discontinue
the treatment. During treatment gastrointestinal symptoms,
such as abdominal pain and diarrhea, improved markedly.
Increases of sweat production in specific areas such as axillas
or feet, together with a decrease of neuropathic pain, were
reported. Patients also reported weight gain. Body mass index
(kg/m2) increased from 25.376.5 to 27.376.9 (P¼ 0.02) in
patients with normal kidney function, whereas there was no
change in patients with impaired kidney function (22.773.2
vs 23.373.7). Overall NYHA classes did not change
significantly (Table 2).
Clinical end points. A total number of 12 events were
detected in nine patients during ERT. All events were
exclusively observed in patients with impaired kidney
function. Two deaths occurred, one at 10 months after
enrolment due to heart failure (heart weight 820 g) while on
hemodialysis treatment since 12 months and another at 14
months due to mesenteric infarction with extensive bowel
necrosis. Causes of death were confirmed by autopsy.
Initiation of hemodialysis treatment was required in two
male patients who presented initially with chronic kidney
disease stage 4. Episodes of vertigo and ataxia, followed by a
transitory ischemic attack, were observed in one patient.
Cardiac events consisted of myocardial infarction with
subsequent coronary intervention (one patient), coronary
artery bypass grafting (one patient), cardiac pacemaker
implantation (two patients), and new onset of atrial
fibrillation in two females (see Tables 1a and b).
Echocardiographical measurements
Echocardiography showed that LV end-diastolic posterior
wall thickness (PWT) averaged 11.771.0 at baseline and
decreased significantly to 10.770.7 mm after treatment in
patients with preserved kidney function (P¼ 0.017). A
reduction of PWT from 14.072.1 to 13.472.3 mm was also
observed in patients with impaired kidney function but did
not reach significance (see Table 2). Patients with impaired
baseline kidney function had a significant more pronounced
LV hypertrophy (14.072.1 vs 11.771.0 mm, P¼ 0.005). Left
ventricular fractional shortening and wall thickening-fraction
(WTF), as a parameter for regional myocardial function of
the posterior wall, were within normal range at baseline and
remained stable during the study period in all patients (see
Table 2 for details). The 6 female patients showed a reduction
Table 1a | Patient demographic and clinical data at baseline
Pat./Sex/
Family
Follow-up
in months
Age at diagnosis/
onset of therapy Major organ manifestation
1/m/I 25 43/43 P, LVH, AH
2/m/II 34 44/53 P, LVH, VP, AH, CAD, CVS
3/m/III 37 39/41 P, LVH, AH, CVS
4/m/IV 29 49/50 P, LVH, AH, CAD, CABG, CVS
5/m/V 18 31/33 P, LVH, AH, CVS
6/m/VI 12 36/41 P, VP, PAD
7/m/VII 24 33/34 P, LVH, VP, CVS
8/m/VI 33 42/46 P, LVH, VP, AF
9/m/V 13 29/29 P, LVH, VP
10/f/VII 23 42/43 P
11/m/VII 26 33/34 P, LVH, VP
12/m/VIII 24 30/30 P, LVH, AH, CVS
13/f/II 13 54/54 P, LVH, VP
14/m/XI 11 37/37 P
15/m/II 28 24/32 KTX, LVH, VP, AH
16/m/II 36 41/50 KTX, LVH, VP, Stroke
17/m/IX 23 28/55 KTX, LVH, VP, PM, CAD,
CABG, Stroke
18/m/X 25 24/34 ESRD, LVH, VP, AH
19/m/XII 15 36/37 ESRD
20/f/V 14 56/57 LVH, VP
21/f/X 33 55/55 LVH, AH
22/m/VIII 24 27/31 LVH
23/f/XIII 12 24/39 AH, CVS
24/f/VII 23 39/40 —
25/m/XIV 13 31/38 —
m, male; f, female; P, 24 h proteinuria430 mg ; LVH, left ventricular hypertrophy; AH,
arterial hypertension; VP, valvulopathy; CAD, coronary artery disease; CVS,
cerebrovascular symptoms; CABG, coronary artery bypass graft; PAD, peripheral
arterial disease; AF, atrial fibrillation; KTX, kidney transplantation; PM, pace maker;
ESRD, end-stage renal disease.
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of PWT from 13.2 to 11.7 mm and WTF was unchanged
(27712 vs 28712%).
Kidney function
GFR measurements and 24 h urinary protein excretion at
baseline and follow-up were carried out in 20 patients, three
of them with a functioning kidney graft. Two patients who
were on hemodialysis treatment at baseline and three patients
who progressed to end-stage renal disease 0.5, 3, and 6
months after the onset of ERT were excluded from the GFR
measurements. Since it is believed that a-GalA production by
the grafted kidney is sufficient to prevent local GL3
accumulation, we did not expect functional impairment
and a change in proteinuria in transplanted patients due to
Fabry disease. Among the remaining 17 patients, nine had a
baseline GFR above 90 ml/min/1.73 m2 and eight below
90 ml/min/1.73 m2. In patients with normal kidney function,
GFR was measured with a mean of 115718 ml/min/1.73 m2,
which declined to 102714 ml/min/1.73 m2 (NS). In the
remaining patients, mean GFR at presentation was
Table 1b | Patient clinical data at baseline and follow-up
GFR (ml/min/1.73 m2) Proteinuria (mg/day) Concomitant therapy Blood pressure (systolic/diastolic in mmHg)
Pat./Sex/Family Bs Fu Bs Fu Bs Fu Bs Fu
1/m/I 7a ESRDb 3402 NA ACE — 130/80 130/80
2/m/II 48 26 3020 333 BB ACE, BB, D 120/60 80/60
3/m/III 41a 36 2300 3122 BB, D ACE, CCB 125/88 160/81
4/m/IV 11a ESRDc 2132 NA ACE, CCB ACE, BB, D 142/82 105/70
5/m/V 24 ESRDd 2030 NA ACE, D ACE 153/101 140/70
6/m/VI 81 71 1752 1060 — — 108/76 90/50
7/m/VII 97 87 1550 2263 — — 134/79 133/87
8/m/VI 82 65 1293 321 D, CCB ARB, BB, D 122/83 125/96
9/m/V 113 101 500 o30 — — 167/82 128/85
10/f/VII 126 104 302 338 — ACE 130/80 116/83
11/m/VII 106 110 169 359 D — 128/91 130/73
12/m/VIII 87 88 66 o30 — — 161/88 153/99
13/f/II 95 113 637 1180 — ACE 101/70 124/97
14/m/XI 123 121 1914 862 — ACE 132/92 144/79
15/m/II 56KTX 46KTX 60KTX o30KTX ARB ARB 103/77 160/85
16/m/II 81KTX 118KTX o30KTX o30KTX D ARB, A, D 104/79 110/60
17/m/IX 50KTX 43KTX o30KTX o30KTX ACE, D ACE, D 108/77 140/70
18/m/X ESRD 49KTX ESRD o30 — ACE, BB 120/90 120/70
19/m/XII ESRD NA ESRD NA — — 115/53 94/57
20/f/V 78 82 o30 287 BB BB 133/92 159/84
21/f/X 73 39 o30 o30 D ACE, D 153/105 116/85
22/m/VIII 80 73 o30 o30 BB — 120/85 124/85
23/f/XIII 142 78 o30 o30 ARB ARB 150/90 120/70
24/f/VII 135 114 o30 o30 — — 105/98 114/90
25/m/XIV 93 93 o30 o30 — — 108/73 127/96
GFR, glomerular filtration rate; Bs, baseline; Fu, follow-up; m, male; f, female; ESRD, end-stage renal disease CKD V; ESRD, developed; KTX; kidney transplantation; NA, not
analyzed; ACE, angiotensin-converting enzyme inhibitor; ARB, angiotensin-II receptor blocker; BB, beta blocker; A, amiodarone (active agent); CCB, calcium channel blocker; D,
diuretic.
aGFR calculated by the MDRD equation.
b0.5 month after initiation of enzyme replacement therapy.
c3 month after initiation of enzyme replacement therapy.
d6 month after initiation of enzyme replacement therapy.
Table 2 | Baseline and follow-up data of 25 patients with a GFR490 ml/min/1.73 m2 and a GFRo90 ml/min/1.73 m2
GFR490 ml/min/1.73 m2 (n=16) GFRo90 ml/min/1.73 m2 (n=16)
Baseline Follow-up P Baseline Follow-up P
Proteinuriaa (mg/day) 8457714b 8347816 0.96 20917743c 102471216 0.3
SCrea (mg/dl) 0.7970.13 0.8070.12 0.72 1.270.42d 1.4470.8 0.09
GFR (ml/min/1.73 m2) 115718 102714 0.15 71717d 60723 0.039
PWT (mm) 11.771.0 10.770.7 0.017 14.072.1 13.472.3 0.22
FS (%) 35710 4174 0.09 3478 3777 0.48
WTF (%) 30714 43716 0.07 42717 36720 0.26
NYHA class 1.270.5 1.670.5 0.19 1.570.6 1.870.8 0.2
BMI (kg/m2) 25.376.5 27.376.9 0.039 22.773.2 23.373.7 0.24
GFR, glomerular filtration rate; SCrea, serum creatinine; PWT, posterior wall thickness; FS, fraction of shortening; WTF, wall thickening fraction; NYHA, New York Heart
Association; BMI, body mass index.
Patients with end-stage renal disease (n=8) were excluded for proteinuria, SCrea, and GFR measurements.
aProteinuria4100 mg/day.
bn=6.
cn=4.
dn=8.
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71717 ml/min/1.73 m2 and deteriorated significantly to
60723 ml/min/1.73 m2 (P¼ 0.04). Accordingly, serum crea-
tinine remained stable (0.7970.13 vs 0.8070.12 mg/dl) in
the first group and tended to increase in the latter group
without reaching significance (1.270.4 vs 1.470.7 mg/dl,
P¼ 0.09). In female patients (n¼ 6), GFR declined from
108730 to 94730 ml/min/1.73 m2 mainly due to deteriora-
tion of GFR in two patients (73–39 and 143–78 ml/min/
1.73 m2, respectively). On biopsy, both showed an involve-
ment of podocytes and mesangial cells but no endothelial
GL3 deposition. The amount of chronic damage in tubulo-
interstitial tissue was 15–20% in the first patient. The latter
patient showed no glomerulosclerosis but immune staining
was positive for IgA suggesting additional IgA nephritis.
At baseline, proteinuria was present in 12 of 19 patients
not on renal replacement therapy (mean 1.5771.05 g/day).
There was a significant difference at baseline for patients with
normal and impaired kidney function (0.8570.72, n¼ 6 and
2.370.79 g/day, n¼ 6; P¼ 0.007). Two patients with heavy
baseline proteinuria and CKD stage 4 progressed to end-stage
renal disease and could not be included in follow-up
evaluation. For the remaining 10 patients, proteinuria did
not change significantly during treatment period (1.3470.94
vs 1.0170.97 g/day). There was no significant change in
proteinuria during treatment period in either group (Table 2).
Table 1a and b outlines single 24 h urinary protein excretion
of patients.
Kidney histology and autopsy results
Seven patients had biopsies in our center (three male and
four female patients) before the start of ERT. The male
patients had glomerulosclerosis of less than 5, 15–20, and
35–40% and showed, apart from podocyte and mesangial
involvement, GL3 deposits in the vascular endothelium.
There was only one female patient who showed glomerulo-
sclerosis (15–20%), all had podocyte and mesangial GL3
deposits but no endothelial involvement. A correlation in
respect to glomerulosclerosis and the course of kidney
function under ERT could not be detected. The patient
who died after 14 months of ERT due to mesenteric
infarction had no GL3 depositions in his vascular endo-
thelium of the mesenteric vessels, coronary, and glomerular
arteries. However, there was significant GL3 detection in the
lamina muscularis of the mesenteric artery and in the
podocytes of the kidney. The patient who died after 10
months of ERT, due to sudden cardiac death, had only a
slight general arteriosclerosis but a high-grade stenosis of the
right coronary artery. No endothelial GL3 deposits could be
detected. There was a massive LV hypertrophy (PWT of
19 mm) and a markedly dilated left and right ventricle of the
heart.
DISCUSSION
Treatment of Fabry disease with r-haGalA can reverse
substrate storage in the lysosome. Prospective clinical trials
in patients with mild to moderate disease have demonstrated
GL3 clearance from different cells of skin, heart, and the
kidney as surrogate end points in parallel with an improve-
ment of symptoms. This study enrolled a cohort of 26
patients with moderate to very advanced Fabry disease and
investigated whether cellular GL3 clearance is followed by a
long-term benefit. One might anticipate that response to ERT
may differ depending on the stage of organ involvement at
initiation of treatment.
The main findings of the present study were that patients
with renal dysfunction at study entry also displayed more
severe cardiac hypertrophy as assessed by left ventricular wall
thickness. It was striking to see that only patients with
impaired renal function developed devastating end points.
There were clear differences in the response to ERT
depending on the baseline characteristics of the patients.
GFR as well as myocardial hypertrophy was not stabilized in
those patients with impaired kidney function at baseline. In
accordance with published data, we observed a reduction of
posterior left ventricular wall thickness during ERT in
patients with normal kidney function.7,9 How should these
data be interpreted in respect to the positive results from the
Fabrazymes phase 3 and phase 3 open label extension
study?5,7 Of note is the comparatively young age of the
patients (on average 30 years) in these studies, whereas the
average age of our patients was 41 years. According to natural
history data, most Fabry patients have already developed
chronic kidney disease by the age of 40 years.10–12 In our
group, eight of the 26 patients required renal replacement
therapy and five others had severe renal involvement,
documented by pronounced proteinuria. Baseline kidney
function in the phase 3 and phase 3 extension study was
entirely normal.5,7 Subgroup analysis of the study by Wilcox
et al.7 revealed that three of 58 patients had an increase of
more than 50% in their serum creatinine levels during
follow-up over 36 months. Common clinical characteristics
of the three patients were renal scarring and sclerosis of more
than 50% of their glomeruli, an age above 40, and a urinary
protein/urinary creatinine ratio greater than or equal to 2.
Thus, we can assume that the patients displaying renal
impairment in our cohort would also represent advanced
and/or irreversible histological kidney damage. The anticipa-
tion that rapid lysosomal clearance of GL3 from the
glomerulus or the interstitium will translate into regression
or remission of kidney disease may hold true in early stages of
the disease. Advanced stages with remodelling of organ
architecture, matrix accumulation, and deposition, may not
respond to ERT, if at all during prolonged treatment.
Certainly, the design of the phase 2 and 3 trials did not
allow detecting improvements of kidney function during
treatment, since function was normal at baseline and
proteinuria was absent. Branton et al. followed the natural
history of a series of patients demonstrating a progression
from the onset of chronic renal insufficiency to end-stage
renal disease during 4 years.11 Fourteen patients had an
average loss of mean GFR of 12.2 ml/min/year. This loss of
renal function over time is comparable with that seen in
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patients with diabetic nephropathy not receiving angiotensin
antagonist therapy and faster than a number of other renal
diseases, including many forms of glomerulonephritis.13
Given that, we suggest that the GFR loss of 5.8 ml/min/year
in the severely affected patients of the cohort studied here
might represent a slowing of disease progression. On the
other hand, excluding two nonprogressors with a borderline
baseline GFR (Pat. 12, GFR 87 ml/min/1.73 m2 and Pat. 20,
GFR 78 ml/min/1.73 m2), GFR decline of the remaining
patients was 9 ml/min/year. However, the small number of
patients studied and the limited observation time does not
allow firm conclusions from this comparison.
The results observed in our patients with mildly impaired
or normal renal function are encouraging and are in
agreement with the data reported by Eng et al.5 and Wilcox
et al.7 as well as registry data recently published by Beck and
co-workers.14 Proteinuria was present in overall 12 patients
and was significantly higher in patients with impaired kidney
function indicating a more advanced stage of kidney disease.
Notably, among the five patients with the highest levels of
proteinuria, three progressed to end-stage renal disease within
the observation period. However, there was no significant
change in proteinuria during treatment period regardless of
kidney function. Recently, consensus has been achieved to
combine enzyme replacement with cardiovascular and reno-
protective co-medications, where needed.15 This recommen-
dation is based on good clinical care or treatment guidelines
for cardiologists and nephrologists in general. However,
standard treatment of proteinuria with angiotensin antagonist
therapy in Fabry patients has not yet been attempted
systematically and should be subject to further studies.
Development of cardiomyopathy without renal damage
has led to the discovery of a so-called cardiac variant and vice
versa renal variants have been described recently.16,17 However,
a combination of kidney and heart disease, demonstrated by
left ventricular hypertrophy, was present in most of the
patients, which is in accordance with existing literature.18,19
Echocardiography demonstrated a significant decrease in left
ventricular wall thickness during therapy only in the patients
with less severe kidney involvement. Routine parameters of
global LV-function failed to show any impairment of global
systolic left ventricular function at baseline and follow-up
regardless of baseline kidney function. This leads to the
hypothesis, parallel to the observation in renal disease, that
cardiac involvement cannot be reversed once cardiomyocyte
infiltration exceeds certain limits. This is supported by biopsy
studies showing cardiomyocytes with perinuclear GL3 deposits
and interstitial widening due to intercellular fibrosis, which
was more pronounced in patients with LVH.20
Another question is the relation between the occurrence of
clinical end points and the extent of renal dysfunction or
cardiac hypertrophy as surrogate parameters of disease
severity at baseline. In this study, a striking distinction
between those with renal impairment and cardiac hyper-
trophy and those with less severe disease affection was found.
Not a single patient with normal kidney function reached a
clinical end point. In contrast, nine of 16 patients with a GFR
below 90 ml/min experienced 12 end points during treat-
ment. This supports the assumption that ERT cannot
profoundly influence disease progression and clinical out-
come once the damage from the underlying disease is far
advanced.21 The definite answer can be given by a
randomized controlled trail in this subgroup of patients.
First clinical data from a controlled trial indicate that ERT
may slow the progression of kidney disease significantly (S
Waldek, personal communication). Vice versa, patients with
normal renal function experienced considerable weight gain
during treatment, a sensitive parameter of well being.
The subgroup of six female patients participating in this
study showed a good response to ERT in respect to reduction
of LV mass. Kidney function was normal at baseline and
remained stable over the study period except of two patients,
one with renal sclerosis about 20% and another one with
concomitant IgA nephritis. However, we also want to point
out that recent data suggest that although X-linked, many
women may be affected more severely than assumed in the
past.22
One limitation of the present study is the lack of a control
group. However, patients were referred for evaluation and
initiation of treatment, shortly after publications of the phase
2/3 trials and approval of ERT in Europe,5,8 and it was not in
accordance with ethical considerations to enrol patients into
a placebo treatment arm. Although the use of angiotensin-
converting enzyme inhibitors or angiotensin receptor block-
ers as a possible confounding factor cannot be excluded, a
statistically significant impact between specific co-medica-
tion, blood pressure, and PWT could not be detected. As the
present study has an explorative design, a composite primary
end point was not specified a priori. A second limitation is
the inclusion of patients on hemodialysis treatment in the
evaluation of LV-hypertrophy regression. Additional risk
factors for LVH may have been operative, such as anemia and
hypertension, which may have counterbalanced some of the
effects ERT has exerted on the left ventricle. However,
hypertension was well controlled and average hemoglobin
levels were normal throughout the study.
In summary, patients with Fabry disease at the stage of
severe organ involvement and impaired renal function may
develop cardiovascular and renal end points despite ERT.
There are potential benefits of ERT in patients with less
advanced disease manifestation. Due to high costs of ERT,
physicians hesitate to start treatment early during the course
of the disease. Although lacking a control group, the present
results of this study suggest that ERT should be started best
before proteinuria, LVH, or any other organ involvement has
developed in order to preserve kidney and cardiac function
prior to irreversible organ damage.
MATERIALS AND METHODS
Patients and data collection
Twenty six patients (six females), mean age 41.478.9 years (range
29–57), with known Fabry disease were consecutively referred to the
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outpatient clinic of the University Hospital, Wu¨rzburg between June
2001 and August 2003. Diagnosis was made at a mean age of
37.379.4 years by kidney (n¼ 7) or cardiac biopsy (n¼ 1), through
family screening (n¼ 11), by diagnosis of angiokeratoma (n¼ 3), by
neurological examination (n¼ 2), cornea verticillata (n¼ 1), or
blood spot screening and measurement of a-GalA activity (n¼ 3).
Patients received baseline and follow-up evaluation using a
standardized protocol as described previously.23 Nine patients had
normal kidney function with a GFR above 90 ml/min/1.73 m2
whereas GFR was impaired in 16 patients (o90 ml/min/1.73 m2),
including those necessitating renal replacement therapy.
Echocardiography
End-diastolic (WTed) and end-systolic (WTes) wall thickness of the
posterior wall as well as fractional shortening was measured using
standard M-mode echocardiographical methods from parasternal
long axis views (GE Vingmed System V, Horten, Norway; 2.5 MHz).
WTF, as a parameter for regional myocardial function of the
posterior wall, was calculated by WTF¼ [(Wtes–WTed)/
WTed] 100. All examinations were carried out on the same device
by the same investigator. Measurements were recorded and analyzed
by one physician blinded to patients and time of examination.
Renal function
Renal function testing consisted of glomerular filtration rate
assessment by clearance of Technetium-99 m labelled DTPA (99Tc
DTPA). A complete urine analysis was carried out and 24 h urine
was collected to determine urinary protein excretion. The MDRD
equation was used to estimate the GFR in three patients where
DTPA clearance was not available at baseline.
Enzyme replacement therapy
r-haGalA (agalsidase b; Fabrazymes, Genzyme, Cambridge, MA,
USA) was administered intravenously at a dose of 1 mg/kg of body
weight. Infusions were given every second week and started at an
initial rate of 0.3 mg/min, which was gradually raised to 0.6 mg/min.
Medical history, physical examination, and routine blood tests were
performed at each visit. Blood pressure, heart rate, and body
temperature were taken before and after every infusion. All patients
were restudied every 12 months. The study was carried out
according to ‘The Declaration of Helsinki Principles’ of 1964, as
last revised in Edinburgh in October 2000, and was approved by the
local Ethics Committee. Informed consent was given by all
participating patients.
Clinical end points
Clinical end points consisted of death, implementation of renal
replacement therapy, cerebrovascular event (defined as transitory
ischemic attack and stroke), and cardiac event (defined as myocardial
infarction, percutaneous coronary intervention, coronary bypass
grafting, and any arrhythmia or pace maker implantation).
Statistical analysis
Data are presented as mean7standard deviation of mean.
Differences between baseline and follow-up (mean of 22.778.2
months) were tested using two tailed, paired Student’s t-test. A P-
valueo0.05 was considered to indicate significance. Univariate
regression analysis was carried out for blood pressure, medication
with angiotensin-converting enzyme inhibitors and angiotensin
receptor blockers to detect possible influence on PWT.
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